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Diabetes, cardiovascular disease and the 
microcirculation
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Abstract 
Cardiovascular disease (CVD) is the leading cause of mortality in people with type 2 diabetes mellitus (T2DM), yet 
a significant proportion of the disease burden cannot be accounted for by conventional cardiovascular risk factors. 
Hypertension occurs in majority of people with T2DM, which is substantially more frequent than would be antici-
pated based on general population samples. The impact of hypertension is considerably higher in people with 
diabetes than it is in the general population, suggesting either an increased sensitivity to its effect or a confounding 
underlying aetiopathogenic mechanism of hypertension associated with CVD within diabetes. In this contribution, we 
aim to review the changes observed in the vascular tree in people with T2DM compared to the general population, 
the effects of established anti-diabetes drugs on microvascular outcomes, and explore the hypotheses to account for 
common causalities of the increased prevalence of CVD and hypertension in people with T2DM.
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Background
Type 2 diabetes mellitus (T2DM) and hypertension 
are established risk factors for cardiovascular disease 
(CVD), and people with T2DM and hypertension have 
an increased risk of cardiovascular (CV) mortality com-
pared with those with either condition alone [1]. This 
excess risk is suggested to be due to the synergistic effect 
on large and small blood vessels simultaneously, thereby 
reducing the potential for compensatory collateraliza-
tion protecting organs from the adverse consequences of 
damage to either vascular bed. The principle role of the 
vasculature is to deliver oxygen and nutrients to the tis-
sues—whether that is the heart, the brain, or the kidney. 
The functional changes occurring in T2DM and hyper-
tensive conditions significantly alter the haemodynamic 
stress on the heart and other organs. However, the dif-
ferent physiology, mechanisms and changes at the micro-
vascular level differ from those at the macrovascular level 
in T2DM and hypertension, which in turn have signifi-
cant implications with respect to future CV risk.
Vascular anatomy in cardiovascular disease
Although there is increasing evidence that the venous 
tree regulates cardiac output and total body circulating 
fluid, the majority of the pathology occurs within the 
arterial circulation. Broadly, the arterial tree spanning 
from the large coronary artery to the minute capillar-
ies is comprised of four components—elastic (conduit) 
arteries, muscular conduit arteries, muscular resistance 
arterioles and capillaries—each representing a distinct 
vessel system (Fig.  1) with a distinct role to play in the 
circulation [2]. Elastin and collagen, the major structural 
proteins of elastic and muscular conduit arteries, respec-
tively, provide mechanical strength to the vessel wall for 
the conduct of blood from the heart to peripheral organs 
[3]. Their abundance along the longitudinal aortic axis is 
largely determined during the developmental stage and 
remains quite stable after that, due to the extremely low 
turnover [2]. The basic architecture of the arterial tree 
displays a progressive change from predominantly elas-
tin and vascular smooth cells at the aortic arch, gradu-
ally giving way to a collagen rich media by the distal aorta 
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(Table  1). Over the last five centimetres of the thoracic 
aorta and aortic branches, there is a rapid transition to 
a predominantly collagen and vascular smooth cell mus-
cular artery. In the resistance arterioles and capillaries, 
vascular smooth muscle (VSM) cells become increas-
ingly sparse until these are no more than one cell layer in 
the terminal branches. VSM cells have differing embry-
onic origins in the vessel beds, with proximal elastic 
and muscular vessels derived from ectodermal tissue, 
whereas small muscle beds and arterioles have meso-
dermal origin. Thereby, the formation of microcircula-
tion is a result of the complex process of angiogenesis 
from these mesodermal tissues which takes place dur-
ing embryonic development as well as during adulthood 
(e.g. during hypoxic conditions) [2]. These differences in 
embryology have potential pharmacological and clinical 
consequences later in life as they are thought to trigger 
differential effects of certain classes of vasodilators such 
as calcium channel blockers or α-adrenoceptor antago-
nists on proximal versus distal VSM cells.
Hypertensive target organ damage in people with diabetes
One of the hallmarks of hypertensive vascular damage is 
increased arterial stiffness in the large elastic arteries [4]. 
Arterial stiffness contributes to the pathogenesis of ath-
erosclerosis and independently predicts CV death after 
adjustment for hypertension, age and gender in patients 
with end stage renal failure [4], essential hypertension [5] 
and T2DM [6]. Greater arterial stiffness [7] and vascular 
endothelial cell dysfunction [8] were reported in patients 
with T2DM. Concomitant T2DM and hypertension is 
also associated with greater arterial stiffness than either 
condition alone, independent of conventional CV risk 
factors such as gender, smoking history and ethnicity [9, 
10]. Furthermore, in people with diabetes, the cell types 
which maintain integrity of the vascular wall in the mac-
rocirculation are more prone to damage, particularly in 
the presence of CV risk factors [11]. These macrovascu-
lar changes, however, are evident in the pre-diabetic and 
pre-hypertensive stages, raising the possibility of a vascu-
lar aetiology in the pathogenesis of diabetes and hyper-
tension [12, 13].
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Fig. 1 Structural hierarchy of arterial tree in health and disease conditions
Table 1 Characteristics of components of the arterial tree
BP blood pressure
Elastic arteries Muscular conduit arteries Muscular resistance arterioles Capillaries
Diameter > 2 mm 150 µm–2 mm 8–150 µm < 8 µm
Regulation Media structure > endothelium Media structure and endothelium Endothelium > media structure Endothelium only
Function Conduit: elastic recoil (diastolic BP) Conduit: minor resistance Resistance Nutrient and waste exchange
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Several mechanisms have been proposed to account for 
the greater arterial stiffness in patients with T2DM and 
hypertension. Elevated glycaemia is a major determinant 
of both arterial stiffness and carotid intimal media thick-
ness (IMT), the latter of which is another well-established 
measure of blood pressure (BP)-related damage indepen-
dently predictive of CV events [14, 15]. Chronic hyper-
glycaemia is known to be associated with the build-up of 
advanced glycation end-products (AGEs), which, lead to 
arteriosclerosis [16]. This could account for the impact 
of glycaemia on endothelial function. A meta-analysis 
reported that an increase in carotid IMT by 0.13  mm 
is associated with an increase in CV risk by nearly 40% 
in patients with T2DM compared with control subjects 
[17].
Oxidative stress is an alternative mechanism which has 
been suggested to exacerbate macrovascular damage in 
patients with diabetes. Reactive oxygen species (ROS) can 
be induced by multiple biochemical pathways including 
activation of the polyol pathway and the non-enzymatic 
formation of AGEs [16, 18, 19], each of which could dam-
age the endothelial system. Supportive evidence includes 
the observation that anti-oxidant drugs inhibit the patho-
logical neovascularisation of endothelial cells by attenu-
ating the production of these ROS under hyperglycaemic 
conditions [20]. An alternative, possibly complementary, 
mechanism of vascular damage is the inactivation or 
suppression of nitric oxide (NO) by oxygen-derived free 
radicals; interestingly this has been associated with gly-
caemic variability rather than by glycaemia itself [21]. 
This observation is supported by the association between 
glycaemic variability, as measured by mean amplitude of 
glycaemic excursion (MAGE), and clinically relevant out-
comes [22]. Glycaemic variability has been shown to be a 
strong prognostic factor for poorer cardiac outcomes in 
subjects with T2DM after acute myocardial infarction, 
supplanting other established measures of glycaemia, 
including glycated haemoglobin (HbA1c), fasting plasma 
glucose or postprandial glucose alone [23]. The use of 
dipeptidyl peptidase-4 (DPP-4) inhibitors to reduce daily 
glucose fluctuations has been associated with a reduc-
tion in oxidative stress and inflammation [24]: within 
a 3-month period, reduction in glycaemic variability 
caused a commensurate and proportionate reduction in 
carotid IMT [25], suggesting that glycaemic variability 
could be a potentially reversible early therapeutic target 
to partially address the increased CVD risk in those with 
T2DM.
Further, in chronic vascular conditions, the incidence 
of macrovascular events is usually accompanied by sig-
nificant and progressive microvascular pathological 
impediments and dysfunction. The effects of increas-
ing peripheral vascular disease (PVD) risk on indices of 
microvascular dysfunction confirm presence of multiple 
predictors of microvasculopathy and health outcomes of 
macrovascular events: studies of skeletal muscle micro-
circulation in rat models indicate greater heterogeneity 
in perfusion distribution and reduced flexibility in micro-
vascular network, progressive decrease in NO bioavail-
ability, arachidonic acid metabolism, as well as myogenic 
activation and adrenergic constriction [26].
The role of microcirculation is universal
The emphasis on large vessel diseases such as increased 
arterial stiffness and carotid IMT ignores the contribu-
tion of the microcirculation to CVD. Whilst the asso-
ciation between disease of the conduit or resistance 
arteries and CVD has been explored and well-charac-
terised, much of the variance in the increased frequency 
but also clinical symptoms of CVD in diabetes remains 
unexplained. For example, in patients with heart failure 
(HF), the presence of diabetes increases the risk of longer 
hospital stays, recurrent HF hospitalisations and mortal-
ity in comparison with patients without diabetes [27–29]. 
The lack of association between hyperinsulinemia and 
insulin resistance in microvascular dysfunction was ques-
tioned in the past [30] but it is now well-established that 
endothelial dysfunction of microvascular origin, in the 
absence of obstructive epicardial coronary disease, such 
as myocardial ischemia due to coronary stenosis may 
lead to clinical manifestation and symptoms indicative 
of microvascular angina even at rest [31]. However, the 
role of overall, conventionally assessed, improved glycae-
mic control on microvascular function is unclear [32]. 
Therefore, although AGEs or persistent insulin resistance 
are speculated to cause progressive haemodynamic dys-
function and increased CV events in patients with diabe-
tes [28], the exact mechanisms associating hypertension 
and atherosclerosis in the background of diabetes are 
not clearly understood. Yet the aspect of microcircula-
tory function once unfolded may lead to the development 
of future novel therapeutic targets especially in subjects 
with diabetes.
The microcirculation is a network of blood ves-
sels < 150  µm in diameter, comprising arterioles, capil-
laries and venules. This network is responsible for the 
primary function of the vascular tree and regulation 
of tissue perfusion for optimal exchange of gases and 
removal of metabolic waste products [33] and may con-
tribute to the unexplained variance in the association 
between T2DM and hypertension. There are significant 
differences in the way small arteries remodel in response 
to hypertension in people with or without T2DM. In 
patients with essential hypertension alone, the media-
to-lumen ratio of small arteries is increased due to 
reduced lumen and external diameter and greater media 
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thickness, with minimum changes in the total amount 
of wall tissue (Fig.  1) [34]. These structural alterations 
in small arteries due to inward eutrophic remodelling 
without net cell growth, result in decreased vasodilator 
reserves and changes in the distensibility of arterioles 
[35, 36]. On the contrary, in patients with T2DM, the 
media cross-sectional area of small vessels is increased, 
suggesting hypertrophic remodelling [37]. The mecha-
nisms underlying hypertrophic remodelling may include 
increased wall stress due to an impaired myogenic 
response of small arteries in T2DM [38]. The manifesta-
tion of endothelial dysfunction in T2DM may be related 
to increased microvascular permeability to large mole-
cules, such as albumin [39]. Furthermore, in T2DM, vas-
cular dysfunction at the capillary network can alter the 
insulin delivery and thus, the impaired insulin sensitivity 
[40]. Linking these observations, impaired microvascular 
auto-regulatory myogenic responses in populations with 
T2DM predicts urinary albumin excretion rate (UAER), 
and accounts for its association with adverse cardiac 
remodelling [41, 42]. Finally, alterations in the vascular 
extracellular matrix (increased collagen-to-elastin ratio) 
are observed in the vessel wall of people with T2DM [37], 
probably due to inflammatory and pro-fibrotic changes. 
A recent population-based study reported no difference 
in wall thickness and cross-sectional area of retinal arte-
rioles between healthy, T2DM and hypertensive subjects 
at early stages of disease but greater wall thickness in sub-
jects with a diabetes duration of > 60  months compared 
with other groups, suggesting hypertrophic remodelling 
in T2DM with advancing disease duration [43].
Small arterioles and capillaries also exhibit differential 
vascular remodelling in response to hypertension and 
T2DM. The number of vessels perfused in the vascular 
bed and the arteriolar diameter determine the peripheral 
vascular resistance. Microvascular rarefaction can be due 
to the presence of a reduced number of perfused vessels 
in the vascular bed (functional rarefaction) or reduced 
number of vessels in the tissue (structural rarefaction) 
[44]. In most vascular beds, at a given time, only a frac-
tion of microvessels are perfused, and the non-perfused/
reserved vessels are called upon during high metabolic 
demand. Structural loss of vessels may follow progressive 
non-perfusion. In patients with hypertension and T2DM, 
rarefaction has been consistently reported in myocar-
dial microvessels, resulting in a reduced coronary flow 
reserve. Also, maximal blood flow reduces due to struc-
tural abnormalities in the coronary microcirculation and/
or functional factors such as endothelial dysfunction, or 
systemic inflammation [44–46]. Although not associated 
with atherosclerosis, this predicts cardiac symptoms, 
and may explain the high prevalence of refractory [47] 
and microvascular angina [31], especially in people with 
diabetes, despite normal or only mildly diseased coro-
nary arteries.
Microcirculatory dysfunction: cause or effect?
The microcirculatory changes noted in the retinal and 
renal systems have been extensively studied to under-
stand the predictive role of glycaemic variations early in 
diabetes [48]. Diabetic retinopathy, the leading cause of 
premature blindness among patients with T2DM [49], is 
linked to an increased risk of CV mortality [50]. Changes 
in the retinal microvasculature of healthy individuals are 
independently associated with future risk of T2DM [51] 
as well as congestive HF and CV mortality [52, 53], sug-
gesting a microvascular aetiology in the pathogenesis 
of T2DM. Conversely, in patients with T2DM, before 
the onset of retinopathy, regional differences in retinal 
metabolic changes are reported, without an associated 
regional variance of microvascular haemodynamics [54]. 
These studies confirm an association between develop-
ment and progression of the microvascular disease to 
macrovascular disease—however, the nature of associa-
tion and direction of causal effect has not been estab-
lished. Studies assessing nephropathy, atherosclerosis 
and metabolic syndrome may provide additional evi-
dence to support this.
The effect of anti‑diabetes drugs on microcirculation
The direct effects of anti-diabetes agents on vascular 
structure and function have been studied using different 
microvascular models in short-term studies [55–57]. The 
effects of glucagon-like peptide-1 (GLP-1)-based thera-
pies on microvasculature are heterogeneous. The addi-
tion of liraglutide in patients with T2DM showed either 
amelioration in the microvascular hyperaemic response 
[55] or no effect on peripheral endothelial function [58]. 
Treatment with a DPP-4 inhibitor improved microvascu-
lar function with increased hyperaemia area, and resting 
and peak blood flow in the fasting state [59]. In patients 
with T2DM, saxagliptin treatment normalised the retinal 
capillary flow [56], whereas vildagliptin showed improved 
retinal microvascular blood flow beyond glucose control 
[57]. Overall, although experimental studies reveal early 
beneficial effects of DPP-4 inhibitors and GLP-1 ago-
nists on diabetic microvascular complications, clinical 
data regarding the direct effects of these classes of drugs 
on microangiopathy, independent of glucose control, is 
insufficient and warrants additional studies for confirma-
tion. A recent 12-week, randomised controlled trial in 
patients with T2DM concluded that beneficial effects of 
GLP-1-based therapies on glycaemic control and BP are 
not mediated through microvascular changes [33], sug-
gesting further investigation of GLP-1 agonists’ effects on 
microcirculation. The LEADER study, using liraglutide, 
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was associated with improvements in microvascular 
function beyond the benefit anticipated from epidemio-
logical models [60].
In light of the CV safety concerns with certain anti-dia-
betes drugs [61], the Food and Drug Association (FDA) 
and the European Medicines Agency (EMA) mandated 
demonstration of CV safety of new anti-diabetes drugs as 
part of the approval process [62, 63]. Owing to the large 
enrolled population and longer follow-up duration, evi-
dence from these trials or qualified meta-analyses can 
be used to assess the effects of anti-diabetes drugs on 
microcirculation. Interestingly, in the SUSTAIN-6 and 
LEADER trials, the GLP-1 agonists semaglutide and lira-
glutide, respectively, reduced the incidence of nephrop-
athy [60, 64]—these benefits were not observed with 
the exendin-4 based lixisenatide and exenatide in their 
respective CV outcome trials [65, 66]. This observed het-
erogeneous response may represent differences in the 
effect of the agents or the selected population; the ELIXA 
study enrolled patients with T2DM who experienced an 
acute coronary syndrome, and all studies included indi-
viduals with long-term T2DM with established CVD. 
However, one potential explanation could be a GLP-1 
receptor independent effect of the GLP-1 analogue that 
is not mirrored with the exendin-4 derivatives [67]. Par-
adoxically, the LEADER and SUSTAIN-6 studies also 
demonstrated an increased incidence of retinopathy-
related events [60, 64]—suggested to be due to the dra-
matic reduction in HbA1c in the early phases of these 
trials with osmotic shifts that have been well-character-
ised in trials of other agents, including sulphonylureas 
and insulins. Further, the results are limited by the binary 
outcome of retinopathy, whereas we know that retinopa-
thy is itself a dynamic process that changes with glycae-
mic control.
Evidence from the EMPA-REG and CANVAS tri-
als with the sodium–glucose cotransporter 2 (SGLT-2) 
inhibitors empagliflozin and canagliflozin, respectively 
revealed inconsistent microvascular outcomes in patients 
with T2DM and high CVD risk [68–70]. Although both 
agents demonstrated a favourable effect on selected renal 
outcomes, a higher risk of amputation in toes, feet, or 
legs was observed in patients treated with canagliflozin 
[69, 70]. This might probably be due to the impairment in 
the capillary network perfusion in the lower extremities 
of these patients with established microvascular compli-
cations. However, unlike empagliflozin and canagliflozin, 
short term treatment with dapagliflozin reduced retinal 
capillary flow and stabilised early structural remodelling 
(in arteriolar wall cross-sectional area and wall-to-lumen 
ratio) in patients with T2DM [71]. The understanding on 
mechanism of action of SGLT-2 inhibitors on microcir-
culatory as well as macrovascular changes is limited and 
further research is warranted to explore the above find-
ings. These varying responses in microvascular outcomes 
in different vascular beds suggest direct effects of anti-
diabetes agents on the target organs.
In addition to anti-diabetes agents, statins were 
reported to improve endothelial dysfunction and micro-
vascular reactivity in patients with T2DM and dyslipidae-
mia, suggesting positive outcomes on CV morbidity and 
mortality of these class of drugs [72].
Vascular endothelial growth factor and microcirculation
Vascular endothelial growth factor (VEGF) stimulates 
angiogenesis and can affect the microvascular structure 
and function in patients with T2DM and hypertension 
[73]. In patients with diabetic macular oedema, anti-
VEGF therapy attenuates the progression of angiogen-
esis in retinal microvasculature by acting on endothelial 
cells, which affects the systemic microcirculation as well. 
Treatment with bevacizumab for 6  months in patients 
with metastatic colorectal cancer resulted in reduced 
endothelial dysfunction and capillary rarefaction, as 
assessed by reduction of mean dermal capillary den-
sity and vasodilation in the dorsum of the fingers [74]. 
Therefore, similar to patients with essential hyperten-
sion, bevacizumab can cause increased systemic vascular 
resistance as a result of microvascular rarefaction. Simi-
larly, an intravitreal injection of ranibizumab ameliorated 
vision in patients with macular oedema owing to branch 
retinal vein occlusion by reducing the width and relative 
flow volume in retinal arteries and veins [75].
Microalbuminuria: from epidemiology to clinical practice 
and back again
Clifford Wilson and Paul Kimmelstiel for the first time 
in 1936, described UAER as a feature of glomeruloscle-
rosis with poor prognosis. Since then, the role of UAER 
has evolved from a marker of renal microcirculation to a 
predictor of a host of circulatory defects. Several epide-
miological studies reported elevated UAER as a predic-
tor of future CV events and mortality in diabetes, renal 
failure, hypertension and the general population [76–78]. 
UAER also predicts survival after myocardial infarction 
[79] and stroke [80]. Therefore, UAER or its biochemi-
cal equivalent, albumin:creatinine ratio (ACR), has been 
widely used as a surrogate marker for assessing micro-
circulatory target organ damage in patients with T2DM. 
However, the minimum threshold level of albuminuria as 
a prognostic indicator of microcirculatory defects is still 
debated, since an association has also been observed even 
below the physiological levels that can be measured using 
commercial kits [81]. A link between albuminuria lev-
els and increased risk of microcirculatory defects/CVD 
events (odds ratio [OR] 1.20, 95% confidence interval 
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[CI] 1.08–1.33) was reported at values ≥ 10.5 mg/24 h in 
patients with T2DM [82].
Increased haemodynamic stress and vascular perme-
ability to macromolecules in diabetes can lead to adverse 
CV events [83]. However, in the absence of a clear mech-
anistic pathway linking microalbuminuria to adverse 
CV outcomes, many clinicians consider it as a marker 
of blood pressure exposure. Nevertheless recent mecha-
nistic studies suggest that the systemic microvascular 
disturbances that account for the association between 
microalbuminuria and cardiac target organ damage are 
independent of either acute or long term BP effects [41, 
42].
Microvascular function as an aetiopathogenic step in those 
with diabetes and CVD
Patients with T2DM alone are at a higher risk of CV 
events and CV mortality compared with those with-
out diabetes [84]. The presence of T2DM has a similar 
impact on morbidity and mortality as the history of CV 
event [85]. Structural microvascular damage precedes 
the development of CV events in patients with T2DM 
whereas changes in microvascular function occur before 
microangiopathy [86]. In patients with type 1 diabetes 
mellitus (T1DM), microvascular defects develop several 
years after diagnosis, probably relative to glycaemic con-
trol [87]. On the other hand, in women with a history of 
gestational diabetes [88] and in those at risk of develop-
ing T2DM [89, 90], microvascular defects are manifested 
from the stage of diagnosis. Therefore, the fact that an 
increase in microvascular disease (diabetic retinopathy) 
defines a diagnostic cut-off value for HbA1c indicates 
the presence of early and progressive pathophysiological 
defects even prior to the confirmatory diagnosis based on 
glycaemia.
The link between microangiopathy and functional 
microvascular alterations in T2DM and their association 
with good glycaemic control has been strengthened by 
studies on skin microvascular hyperaemic responsiveness 
[91–93]. The degree of glycaemic control (percentage 
decrease in HbA1c over a 12-month period) was strongly 
associated with percentage improvement in maximum 
hyperaemic response  (r2 = 0.53, p = 0.004), suggesting 
that early microvascular changes in T2DM are potentially 
reversible with glycaemic control [91]. Recent findings 
suggest that early good glycaemic control is associated 
with improved microvascular function in patients with 
T2DM and CVD, but lost in those with prolonged dis-
ease, suggesting early, initial aggressive glycaemic control 
to delay/prevent microvascular complications even in 
patients with co-morbid conditions (CVD) [94]. How-
ever, the association between good glycaemic control 
and microvascular function may not correlate with an 
improvement in CVD event rates. Rosiglitazone, a per-
oxisome proliferator-activated receptor gamma antago-
nist, improved NO-dependent vascular response in the 
skin micro-vessels of patients with T2DM independent 
of glycaemic changes [95], but resulted in a concomitant 
increase in the CV event rate [61]. Interestingly, addi-
tional studies with rosiglitazone indicated an increase in 
the risk of myocardial infarction while it ameliorated the 
risk of stroke.
The relationship between CV risk and microcirculatory 
function has been explored by studying the skin micro-
circulatory reactivity. In patients with an increased risk 
of coronary heart disease (CHD), a strong association 
between skin microvascular function (capillary recruit-
ment and impaired endothelium-dependent vasodila-
tion) and 10-year CHD risk scores (calculated from the 
Framingham risk scores), independent of gender and 
body mass index was observed [96]. Additional stud-
ies assessing the link between skin microvascular func-
tion and risk of CV events supported an association 
between impaired systemic microvascular responses in 
patients with angiographically confirmed atheroscle-
rotic coronary artery disease (CAD) [97, 98]. Despite the 
clear attenuation in microvascular response in patients 
with CAD compared with healthy controls, a direct asso-
ciation between atherosclerotic burden and impaired 
systemic microcirculation could not be established, sug-
gesting the association between CVD and microcircula-
tory function is more complex than assumed. Similar 
findings are supported by a study which showed how 
intensified insulin treatment in subjects with T1DM was 
associated with improvement in skin microcirculation 
versus standard insulin treatment, leading to lower inci-
dence of ischaemic foot ulcers [99]. The role of chronic 
hyperglycaemia in insulin-dependent subjects, on the 
relationship between endothelial-dependent skin vasodi-
lation was associated with HbA1c only and demonstrated 
the lack of direct effect of pre-existing severe micro- or 
macrovascular risk factors or complications with induc-
tion in skin microcirculation and blood flow.
The ethnic variations in microcirculatory function 
reported in studies with European and African-Carib-
bean populations further highlight the complex interplay 
between microvascular function and CV disease. Afri-
can-Caribbean people with T2DM, who have a low risk 
of heart disease despite increased prevalence of salt sen-
sitive hypertension, diabetes and insulin resistance com-
pared to their European counterparts [100], are expected 
to have better systemic microcirculatory responses. On 
the contrary, a study on ethnic differences in microvas-
culature demonstrated impaired microvascular structure 
and function in the general African-Caribbean popula-
tion compared with Europeans [101], which was further 
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impaired in patients with T2DM and was unexplained 
by conventional CV risk factors [102]. The attenuation of 
microvascular function re-confirms the increased risk of 
renal disease [103] and retinopathy in African-Caribbean 
people [104] among other population-based studies. 
Furthermore, our current understanding that impaired 
macrovascular function at different vascular beds follows 
the same mechanism is challenged by contrasting obser-
vations; there is a higher incidence of stroke and HF and 
relative protection from atherosclerotic disease [100] in 
African-Caribbean patients compared with Europeans. 
It also supports the role of microcirculatory dysfunc-
tion in the aetiopathogenesis of stroke. This is further 
supported by data from the atherosclerosis risk in com-
munities (ARIC) study, wherein microvascular damage 
assessed by retinopathy and cerebral white matter lesions 
predicted the risk of future macrovascular dysfunction 
(stroke) [105]. Similarly, elevated UAER, a marker of sys-
temic microcirculatory dysfunction, predicts the risk of 
incident stroke and survival after stroke [80].
Microcirculation and clinical practice
Patients with a low to moderate absolute risk report a 
projected high incidence of CVD and therefore need 
clinical intervention. These decisions, however, are pri-
marily based on the likelihood of a CV event rather than 
complete assessment of an individual risk of developing 
a CV event. Knowledge regarding structural and func-
tional alterations in different microvascular beds in sub-
jects with co-existing T2DM and hypertension, and their 
relationship with macrovascular diseases, can be utilised 
for clinical decision-making. Retinal microvasculature is 
a simple model to investigate in subjects with T2DM and 
can be utilised on a large-scale for translation into clini-
cal practice. Skin microvasculature is another accessible 
model to investigate diabetes-associated microvascular 
complications [106, 107].
Similarly, the ease of measuring ACR using a single 
urine specimen qualifies UAER as a tool for estimating 
the future risk of CV events, which can be translated 
into clinical practice [108]. Therefore, relapse or early 
prevention of progression of urinary albumin excretion 
should be considered a clinical target to reduce the risk 
for CVDs. However, large-scale studies evaluating the 
long-term cost-effectiveness of using UAER as a screen-
ing and therapeutic outcome measure to manage CVD in 
high risk patients (i.e., those with hypertension, history of 
stroke, transient ischaemic attack, myocardial infarction, 
and diabetes) are required for verification of widespread 
clinical investigations.
Conclusions
Over the past few decades, epidemiological studies have 
elucidated the role of impaired microcirculation in peo-
ple with diabetes and aetiopathogenesis of CVD. This 
has led to the recognition of the prevalence of micro-
vascular disease. Furthermore, the prognostic value of 
incidence of microvascular disease in predicting CVD is 
now acknowledged. The focus of present-day epidemio-
logical studies is to understand the association between 
pathological mechanisms and the risk factors to ascer-
tain whether they are targets of therapeutic value or risk 
markers of CVD. These studies have contributed to the 
evidentiary framework in favour of clinical monitoring 
of microvascular function, and spurred the initiation of 
mechanistic studies by redefining our knowledge of vas-
cular disease, particularly in people with diabetes.
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